IgGenix: Funding, Investors & Team (Sep 2026)
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
IgGenix has raised $75.0M across 4 funding rounds on record, the most recent a Series B of $40.0M announced in Feb 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
IgGenix Company Profile and Key Stats
Latest funding round on record: Feb 2023.
IgGenix Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
IgGenix raised $10.0M in an undisclosed round announced in Aug 2020.
11 months later, a Series A of $25.0M was announced in Jul 2021.
9 months later, a Series A was announced in Apr 2022 with no disclosed amount.
10 months later, a Series B of $40.0M was announced in Feb 2023.
IgGenix Founders and Leadership Team
Contact details for the IgGenix team: 2 of 3 have an email address on file.
Start 14-day free trial →IgGenix Funding Compared to Other Biotechnology Startups
IgGenix's latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like IgGenix in Biotechnology and San Francisco
Companies Similar to IgGenix
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
IgGenix Funding FAQs
What does IgGenix do?
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
How much funding has IgGenix raised?
IgGenix has raised $75.0M across 4 rounds on record. The most recent is a Series B of $40.0M announced in Feb 2023.
When did IgGenix last raise funding?
IgGenix's most recent funding round on record is a Series B of $40.0M, announced in Feb 2023.
Who founded IgGenix?
FundedIQ lists Bruce Hironaka (Founder), Stephen Quake (Founder) at IgGenix.
Who is the CEO of IgGenix?
Jessica Grossman MD is listed as CEO at IgGenix.
Where is IgGenix headquartered?
IgGenix is based in San Francisco, California, United States.
How many employees does IgGenix have?
IgGenix is in the 1-10 employee band.
How does IgGenix's funding compare to other Biotechnology startups?
IgGenix's latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's IgGenix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for IgGenix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.